Table II.

Summary of studies that used heparanase inhibitors for the treatment of HCC.

Model	Summary	Cell type	(Refs.)
Human	Downregulation of heparanase enhances the suppression of invasion, migration and adhesion in HCC	HepG2, BEL-7402, and HCCLM3	(77,78)
	Administering 160 mg/day PI-88 produces significant clinical advantages for patients with HCC	Liver cells	(79,80)
Rats	Suramin exerts antitumor activity in HCC through the deactivation of heparanase	Liver cells	(15)

HCC, hepatocellular carcinoma.